# Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients

> **NCT04203095** · — · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** the level of plasma cfDNA CINs

## Key facts

- **NCT ID:** NCT04203095
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-10
- **Primary completion:** 2020-11-11
- **Final completion:** 2021-11-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203095, "Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04203095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*